Selective TYK2 Inhibition in Chronic Plaque Psoriasis Selective TYK2 Inhibition in Chronic Plaque Psoriasis

This articles focuses on oral deucravacitinib, a first-in-class selective tyrosine kinase 2 inhibitor for the treatment of moderate-to-severe chronic plaque psoriasis.Skin Therapy Letter

Source: Medscape Today Headlines - February 15, 2023 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news